.Patrick Wander Endlich

Dr. .Patrick Wander Endlich

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
BCBruno Maia Costa
Bruno Maia Costa
VMVinícius Mengal
Vinícius Mengal
GBGirlandia Alexandre Brasil
Girlandia Alexandre Brasil
APAntônio Augusto Peluso
Antônio Augusto Peluso
JTJonas Thue Treebak
Jonas Thue Treebak
GAGláucia Rodrigues de Abreu
Gláucia Rodrigues de Abreu

29 March 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
FSFabrício Bragança da Silva
Fabrício Bragança da Silva
WRWalckiria Garcia Romero
Walckiria Garcia Romero
WRWender Do Nascimento Rouver
Wender Do Nascimento Rouver
KSKatiane Silva
Katiane Silva
SASimone Alves de Almeida
Simone Alves de Almeida
GAGláucia Rodrigues de Abreu
Gláucia Rodrigues de Abreu

12 August 2024 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
LMLaura Defensor Ribeiro de Melo
Laura Defensor Ribeiro de Melo
ARAntonio Luiz Ribeiro
Antonio Luiz Ribeiro
JOJoão Antonio Queiroz Oliveira
João Antonio Queiroz Oliveira
JMJunia Xavier Maia
Junia Xavier Maia
TSThábata Queiroz Vivas de Sá
Thábata Queiroz Vivas de Sá
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Background Strategies aimed at improving the diagnosis and treatment of cardiovascular diseases (CVD) are of utmost importance. Clinical decision support systems (CDSS) are guided by updated guidelines and may be capable of benefiting screening and early diagnosis initiatives in remote regions. Objective To develop a CDSS for screening hypertension and diabetes mellitus (DM), as well as to assess its feasibility and usability in the context of a primary care setting in a resource-constrained region. Methods This research focused on [...] Abstract Background Strategies aimed at improving the diagnosis and treatment of cardiovascular diseases (CVD) are of utmost importance. Clinical decision support systems (CDSS) are guided by updated guidelines and may be capable of benefiting screening and early diagnosis initiatives in remote regions. Objective To develop a CDSS for screening hypertension and diabetes mellitus (DM), as well as to assess its feasibility and usability in the context of a primary care setting in a resource-constrained region. Methods This research focused on

Verified
Journal Article
Open access
PDF file
LMLaís Almeida Menezes
Laís Almeida Menezes
.E.Patrick Wander Endlich
.Patrick Wander Endlich
Deiviany Santana Santos LimaDeiviany Santana Santos Lima
Deiviany Santana Santos Lima
APA. Augusto Peluso
A. Augusto Peluso
SASimone Alves de Almeida
Simone Alves de Almeida
GAGlaucia Rodrigues de Abreu
Glaucia Rodrigues de Abreu
The renin–angiotensin system (RAS) is the main endocrine and tissular component responsible for controlling cardiovascular homeostasis, which can be modulated by estrogen levels. This study investigated the effects of hormone treatments with estrogen and progestins on angiotensin-(1-7)-mediated [Ang-(1-7)] vasodilation in ovariectomized rats and the possible mechanisms involving the RAS. Female Wistar rats were divided into the following groups: sham (SHAM), ovariectomized (OVX), OVX and treated with 17β-estradiol (E2) (OE2), OVX and treated with E2 and drospirenone (OE2 + DRSP), and OVX and treated with medroxyprogesterone (MPA). Hormonal treatment was delivered via gavage for 28 days. Vascular responses to Ang-(1-7) were assessed in isolated aortic rings, and a Western blot of the thoracic aorta was used to determine the protein levels of angiotensin II (Ang II) type-1 receptor (AT1R), Ang II type-2 receptor (AT2R), Ang-(1-7) receptor (Mas), angiotensin-converting enzyme 2 (ACE2), and endothelial nitric oxide synthase (eNOS). The results showed impaired vascular reactivity caused by ovariectomy. Ang-(1-7) induced vasodilation in the OE2, OE2 + DRSP, and MPA-treated groups, while the administration of the AT2R antagonist (PD123319) or the selective Mas antagonist (A779) increased the extent of vasorelaxation induced by Ang-(1-7) in the OVX + MPA group. There were no differences in the aortic levels of AT1R or ACE2 between the groups, but the MPA group showed significantly increased levels of AT2R and eNOS. We concluded that ovariectomy induced vascular dysfunction linked to RAS regulation, and both estrogen (E2) and progestins differentially restored these parameters.

26 June 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
LGLaís Lopes Gonçalves
Laís Lopes Gonçalves
IAIldernandes Vieira Alves
Ildernandes Vieira Alves
ENErika Ferreira Nicoli
Erika Ferreira Nicoli
Deiviany Santana Santos LimaDeiviany Santana Santos Lima
Deiviany Santana Santos Lima
VLVirginia Soares Lemos
Virginia Soares Lemos
GAGlaucia Rodrigues de Abreu
Glaucia Rodrigues de Abreu
Oestrogen deficiency increases oxidative stress and reduces nitric oxide (NO) bioavailability, contributing to cardiac fibrosis following myocardial infarction (MI). This study investigated whether ellagic acid (EA), a natural antioxidant, attenuates post‐MI cardiac fibrosis in ovariectomized rats by reducing oxidative stress and pro‐inflammatory mediators. MI was induced by coronary artery ligation, and EA (30 mg/kg) was administered orally for 4 weeks. Hemodynamic parameters, collagen deposition, infarct size, matrix metalloproteinase‐8 (MMP‐8), NO, superoxide anion and inflammatory cytokines were assessed. MI resulted in ventricular dysfunction, increased collagen deposition and elevated levels of MMP‐8, interleukin‐6 (IL‐6) and superoxide anion. EA treatment improved hemodynamic function, reduced collagen deposition, decreased MMP‐8, IL‐6 and superoxide anion, and enhanced NO bioavailability. These findings demonstrate that EA mitigates cardiac fibrosis and ventricular dysfunction through antioxidant and anti‐inflammatory mechanisms, highlighting its potential as a cardioprotective compound in post‐MI conditions under oestrogen deficiency.

9 June 2026 in Chemosensors
Verified
Journal Article
Open access
PDF file
RCRafael Mendes Coelho
Rafael Mendes Coelho
TLThaís Lima
Thaís Lima
.E.Patrick Wander Endlich
.Patrick Wander Endlich
PSPriscila Izabela Soares
Priscila Izabela Soares
ÂMÂngelo Rafael Machado
Ângelo Rafael Machado
Lucas Franco FerreiraLucas Franco Ferreira
Lucas Franco Ferreira
Hormones regulate numerous physiological processes and are essential for maintaining metabolic homeostasis. Accurate hormone quantification is crucial for the diagnosis and monitoring of endocrine and metabolic disorders. Electrochemical biosensors have recently emerged as promising platforms for hormone detection, offering simplicity, rapid response, cost-effectiveness, and high sensitivity compared to conventional techniques such as chromatography and mass spectrometry. This review summarizes the advances in electrochemical biosensors for detecting clinically relevant hormones, including cortisol, estrogen, progesterone, thyroid-stimulating hormone, parathyroid hormone, prolactin, and insulin, since 2010. Particular attention has been paid to developments in electrode modification strategies, including nanomaterials, redox enzymes, and novel recognition elements, which significantly improve the sensitivity and selectivity. These advances enable hormone detection at lower concentrations in various biological and environmental matrices. Despite these promising developments, challenges related to sensor stability, fabrication costs, and regeneration procedures limit their large-scale commercialization. Future research should focus on improving robustness, optimizing immobilization strategies, and integrating innovative materials to enhance the analytical performance. Continued collaboration among researchers, engineers, and healthcare professionals is essential. With ongoing technological progress, electrochemical biosensors are expected to play an important role in clinical diagnosis, point-of-care testing, and personalized medicine.